甲状腺乳头状癌中BRAFV600E蛋白表达与基因突变的一致性及其临床意义

摘要

目的 探讨甲状腺乳头状癌中BRAFV600E蛋白表达与基因突变的一致性及其临床病理相关性.方法 分别采用免疫组化SP法与实时荧光定量PCR法检测BRAFV600E蛋白表达与基因突变情况,分析两种检测方法间的一致性;采用χ2检验分析 BRAFV600E与甲状腺乳头状癌的临床病理相关性.结果 BRAFV600E基因突变率为89.3％,蛋白阳性率为88.3％,差异无统计学意义;两种检测结果的符合率为97.0％,Kappa值为0.847,一致性较强.患者年龄＜45岁与≥45岁组的BRAFV600E基因突变率分别为96.8％、85.9％,差异有统计学意义;两种检测方法在有被膜侵犯组的阳性率均高于无被膜侵犯组,差异有统计学意义.结论 两种检测方法存在较强的一致性,免疫组化法可以作为检测基因突变的初筛工具.因突变与患者年龄、被膜侵犯相关,与其他临床病理特征无相关性.%Purpose To investigate the consistency and clinicopathologic correlation of BRAFV600E protein expression and gene mutation in papillary thyroid carcinoma. Methods BRAFV600E protein expression and genn mutation was detected respectively by immunohistochemistry of SP and real time-PCR, then the consistency between the both methods was analyzed by Kappa-test, the correlation between BRAFV600E and clinicopatho-logic parameters was analyzed by Chi-square test in papillary thyroid carcinoma. Results The gene mutation and protein expression rates of BRAFV600E were 89.3％ and 88.3％, respec-tively, the differences were not significant, the concordance rate of the both methods was 97.0％, Kappa value was 0.847, the consistence was higher, meanwhile the mutation rates between age ＜45 and ≥45 were respectively 96.8％ and 85.9％, there were significant differences, the positive rates of the both detec-tion methods were higher in thyroid capsule invaded group than non-invaded group, the differences were significant. Conclusion The both methods have higher consistency, the immunohisto-chemistry can be used as an initial screening tool for detecting gene mutation, the gene mutation of BRAFV600E is significantly associated with age and capsule invasion, the relationship is not found between BRAFV600E mutation and the other clinicopatholog-ic parameters.